Effectiveness of different vaccine platforms in reducing mortality and length of ICU stay in severe and critical cases of COVID-19 in the Omicron variant era: A national cohort study in Iran.
COVID-19
ICU stay
SARS-CoV-2
comorbidity
mortality
vaccine
Journal
Journal of medical virology
ISSN: 1096-9071
Titre abrégé: J Med Virol
Pays: United States
ID NLM: 7705876
Informations de publication
Date de publication:
03 2023
03 2023
Historique:
revised:
24
01
2023
received:
15
11
2022
accepted:
13
02
2023
medline:
30
3
2023
pubmed:
24
2
2023
entrez:
23
2
2023
Statut:
ppublish
Résumé
Various severe acute respiratory syndrome coronavirus 2 vaccines with different platforms have been administered worldwide; however, their effectiveness in critical cases of COVID-19 has remained a concern. In this national cohort study, 24 016 intensive care unit (ICU) coronavirus disease-2019 (COVID-19) admissions were included from January to April 2022. The mortality and length of ICU stay were compared between the vaccinated and unvaccinated patients. A total of 9428 (39.25%) patients were unvaccinated, and 14 588 (60.75%) patients had received at least one dose of the vaccine. Compared with the unvaccinated, the first, second, and third doses of vaccine resulted in 8%, 20%, and 33% lower risk of ICU mortality in the adjusted model, with risk ratio (RR): 0.92, 95% confidence interval (CI): 0.84-1.001, RR: 0.80, 95% CI: 0.77-0.83, and RR: 0.67, 95% CI: 0.64-0.71, respectively. The mean survival time was significantly shorter in the unvaccinated versus the fully vaccinated patients (hazard ratio [HR]: 0.84, 95% CI: 0.80-0.88); p < 0.001). All vaccine platforms successfully decreased the hazard of ICU death compared with the unvaccinated group. The duration of ICU stay was significantly shorter in the fully vaccinated than in unvaccinated group (MD, -0.62, 95% CI: -0.82 to -0.42; p < 0.001). Since COVID-19 vaccination in all doses and platforms has been able to reduce the risk of mortality and length of ICU-stay, universal vaccination is recommended based on vaccine availability.
Substances chimiques
COVID-19 Vaccines
0
Vaccines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e28607Informations de copyright
© 2023 Wiley Periodicals LLC.
Références
Worldometer. COVID-19 coronavirus. https://www.worldometers.info/coronavirus/
Worldometers https://www.worldometers.info/coronavirus/country/iran/
Malli F, Lampropoulos IC, Papagiannis D, Papathanasiou IV, Daniil Z, Gourgoulianis KI. Association of SARS-CoV-2 vaccinations with SARS-CoV-2 infections, ICU admissions and deaths in Greece. Vaccines. 2022;10(2):337. doi:10.3390/vaccines10020337
Arbel R, Hammerman A, Sergienko R, et al. BNT162b2 vaccine booster and mortality due to COVID-19. N Engl J Med. 2021;385(26):2413-2420. doi:10.1056/NEJMoa2115624
Vasileiou E, Simpson CR, Shi T, et al. Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study. Lancet. 2021;397(10285):1646-1657. doi:10.1016/S0140-6736(21)00677-2
Tenforde MW, Self WH, Adams K, et al. Association between mRNA vaccination and COVID-19 hospitalization and disease severity. JAMA. 2021;326(20):2043-2054. doi:10.1001/jama.2021.19499
Keshavarz P, Yazdanpanah F, Rafiee F, Mizandari M. Lymphadenopathy following COVID-19 vaccination: imaging findings review. Academic Radiol. 2021;28(8):1058-1071. doi:10.1016/j.acra.2021.04.007
Sevinc SA, Metin S, Basi NB, Ling J, Cinar AS, Oba S. Effectiveness of inactivated SARS-CoV-2 vaccine (CoronaVac) on intensive care unit survival. Epidemiol Infect. 2022;150:e35. doi:10.1017/S0950268822000267
Piraveenan M, Sawleshwarkar S, Walsh M, et al. Optimal governance and implementation of vaccination programmes to contain the COVID-19 pandemic. R Soc Open Sci. 2021;8(6):210429. doi:10.1098/rsos.210429
Hâncean MG, Lerner J, Perc M, et al. Occupations and their impact on the spreading of COVID-19 in urban communities. Sci Rep. 2022;12(1):14115. doi:10.1038/s41598-022-18392-5
Andrews N, Stowe J, Kirsebom F, et al. COVID-19 vaccine effectiveness against the omicron (B.1.1.529) variant. N Engl J Med. 2022;386(16):1532-1546. doi:10.1056/NEJMoa2119451
Raman R, Patel KJ, Ranjan K. COVID-19: unmasking emerging SARS-CoV-2 variants, vaccines and therapeutic strategies. Biomolecules. 2021;11(7):993. doi:10.3390/biom11070993
Rzymski P, Camargo CA, Fal A, et al. COVID-19 vaccine boosters: the good, the bad, and the ugly. Vaccines. 2021;9(11):1299. doi:10.3390/vaccines9111299
Our world in data. Coronavirus (COVID-19) vaccinations. https://covidvax.live/en/location/irn
Negahdaripour M, Shafiekhani M, Moezzi SMI, et al. Administration of COVID-19 vaccines in immunocompromised patients. Int Immunopharmacol. 2021;99:108021. doi:10.1016/j.intimp.2021.108021
Thompson MG, Stenehjem E, Grannis S, et al. Effectiveness of COVID-19 vaccines in ambulatory and inpatient care settings. N Engl J Med. 2021;385(15):1355-1371. doi:10.1056/NEJMoa2110362
Vahedi A, Tabasi F, Monjazebi F, et al. Clinical features and outcomes of icu patients with COVID-19 infection in Tehran. TANAFFOS (Respiration). 2020;19(4):300-311.
World Health Organization. Clinical management of COVID-19. https://www.who.int/teams/health-care-readiness/covid-19
Russo AG, Murtas R, Tunesi S, Decarli A, Bergamaschi W. Boosters and time from the last anti-COVID-19 vaccine dose: lead public health choices by real-time epidemiological assessment. Epidemiol Prev. 2022;46(1-2):34-46. doi:10.19191/EP22.1.A001.001
Lorenzoni G, Rosi P, De Rosa S, et al. COVID-19 vaccination status among adults admitted to intensive care units in Veneto, Italy. JAMA Netw Open. 2022;5(5):e2213553. doi:10.1001/jamanetworkopen.2022.13553
Lopez Bernal J, Andrews N, Gower C, et al. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on COVID-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. BMJ. 2021;373:n1088. doi:10.1136/bmj.n1088
Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med. 2020;383(27):2603-2615. doi:10.1056/NEJMoa2034577
Selvavinayagam TS, Parthipan K, Subramaniam S, Somasundaram A, Sampath P, Kumar V. Role of COVID vaccine in determining ICU admission and death due to COVID-19 in Tamil Nadu. medRxiv. 2022
Al-Jighefee HT, Najjar H, Ahmed MN, Qush A, Awwad S, Kamareddine L. COVID-19 vaccine platforms: challenges and safety contemplations. Vaccines. 2021;9(10):1196. doi:10.3390/vaccines9101196
Francis AI, Ghany S, Gilkes T, Umakanthan S. Review of COVID-19 vaccine subtypes, efficacy and geographical distributions. Postgrad Med J. 2022;98(1159):389-394. doi:10.1136/postgradmedj-2021-140654
Wu Q, Dudley MZ, Chen X, et al. Evaluation of the safety profile of COVID-19 vaccines: a rapid review. BMC Med. 2021;19(1):173. doi:10.1186/s12916-021-02059-5
Parker EPK, Desai S, Marti M, et al. Emerging evidence on heterologous COVID-19 vaccine schedules-to mix or not to mix? Lancet Infect Dis. 2022;22(4):438-440.
Larkin HD. New data on heterologous COVID-19 vaccine combinations. JAMA. 2022;328(10):916-917.
Tan CS, Collier AY, Yu J, et al. Durability of heterologous and homologous COVID-19 vaccine boosts. JAMA Netw Open. 2022;5(8):e2226335.
Bravata DM, Perkins AJ, Myers LJ, et al. Association of intensive care unit patient load and demand with mortality rates in US Department of Veterans Affairs hospitals during the COVID-19 pandemic. JAMA Netw Open. 2021;4(1):e2034266.
Desai A, Desai P, Mehta J, et al. Measuring the impact of a single dose of ChAdOx1 nCoV-19 (recombinant) coronavirus vaccine on hospital stay, ICU requirement, and mortality outcome in a tertiary care centre. Int J Infect Dis. 2021;113:282-287. doi:10.1016/j.ijid.2021.10.032
Alsaffar WA, Alwesaibi AA, Alhaddad MJ, et al. The effectiveness of COVID-19 vaccines in improving the outcomes of hospitalized COVID-19 patients. Cureus. 2022;14(1):e21485. doi:10.7759/cureus.21485
Le Borgne P, Dellenbach Q, Alame K, et al. The impact of age on in-hospital mortality in critically ill COVID-19 patients: a retrospective and multicenter study. Diagnostics. 2022;12(3):666. doi:10.3390/diagnostics12030666
Grasselli G, Greco M, Zanella A, et al. Risk factors associated with mortality among patients with COVID-19 in intensive care units in Lombardy, Italy. JAMA Intern Med. 2020;180(10):1345-1355. doi:10.1001/jamainternmed.2020.3539
Ssentongo P, Ssentongo AE, Heilbrunn ES, Ba DM, Chinchilli VM. Association of cardiovascular disease and 10 other pre-existing comorbidities with COVID-19 mortality: a systematic review and meta-analysis. PLoS One. 2020;15(8):e0238215.
Hippisley-Cox J, Coupland CA, Mehta N, et al. Risk prediction of covid-19 related death and hospital admission in adults after covid-19 vaccination: national prospective cohort study. BMJ. 2021;374:n2300. https://doi.org/10.1136/bmj.n2300
Nguyen NT, Chinn J, De Ferrante M, Kirby KA, Hohmann SF, Amin A. Male gender is a predictor of higher mortality in hospitalized adults with COVID-19. PLoS One. 2021;16(7):e0254066. doi:10.1371/journal.pone.0254066
Taneja V. Sex hormones determine immune response. Front Immunol. 2018;9:1931. doi:10.3389/fimmu.2018.01931
La Vignera S, Cannarella R, Condorelli RA, Torre F, Aversa A, Calogero AE. Sex-specific SARS-CoV-2 mortality: among hormone-modulated ACE2 expression, risk of venous thromboembolism and hypovitaminosis D. Int J Mol Sci. 2020;21(8):2948.
Villar J, Ariff S, Gunier RB, et al. Maternal and neonatal morbidity and mortality among pregnant women with and without COVID-19 infection: the INTERCOVID multinational cohort study. JAMA Pediatr. 2021;175(8):817-826. doi:10.1001/jamapediatrics.2021.1050
Allotey J, Fernandez S, Bonet M, et al. Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis. BMJ. 2020;370:m3320. doi:10.1136/bmj.m3320
Wang H, Li N, Sun C, et al. The association between pregnancy and COVID-19: a systematic review and meta-analysis. Am J Emerg Med. 2022;56:188-195. doi:10.1016/j.ajem.2022.03.060